Almirall seeks nod for tildrakizumab in Europe: Sun Pharma
Friday, March 24, 2017, 3:41 PM
Drug major Sun Pharmaceutical Industries said Spain-based Almirall S.L has sought regulatory approval from the European Medicines Agency for a new drug, tildrakizumab. The drug is being evaluated for the treatment of moderate-to-severe plaque psoriasis, the two companies said in a statement. In July 2016, Almirall entered into a licensing agreement with Sun Pharma for the development and commercialisation of tildrakizumab in Europe.